Skip to main content
. 2020 May 16;9(5):1237. doi: 10.3390/cells9051237

Figure 3.

Figure 3

Liposomal treatment with ceramide-C6 in methionine-choline deficient (MCD)-induced liver steatosis. (A) Animals fed the MCD diet have significant loss of body weight regardless of treatment with Lip-C6 or Lip-G in comparison with the control diet (CD) group (**** p < 0.0001). (B) This coincided with a strong significant decrease in liver size in comparison with the control diet (CD) group (**** p < 0.0001) without (C) changes in liver/body weight ratio when comparing the control diet with MCD-fed mice. (D,E) No significant differences were observed between alanine transaminase (ALT) and aspartate aminotransferase (AST) levels of animals treated with Lip-C6 or Lip-G in comparison with their specific control condition. (F) Lip-C6 treatment did not exacerbate the MCD diet, as analyzed by hematoxylin and eosin and Sirius Red. (G) NASH CRN scoring system demonstrating changes occurring during Lip-G and Lip-C6 treatment in MCD-fed mice (CD n = 5; CD–Lip-G n = 5; CD–Lip-C6 n = 5; MCD n = 5; MCD Lip-G n = 5; and MCD–Lip-C6 n = 9).